UCLA researchers have developed a CAR-NKT cell therapy that has shown to be more effective than current immunotherapies at fighting cancer in tumor samples from late-stage triple-negative breast cancer patients.

While personalized treatments can cost six figures and require weeks to manufacture, this therapy can be mass-produced from donated blood stem cells and stored ready-to-use at about $5,000 per dose.

The same cell product could potentially be used to treat multiple solid tumors like ovarian, pancreatic and lung cancers — all of which express the protein mesothelin.

A new study in Nature reveals that patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found.

A new national study led by Trisha Amboree, Ph.D., at MUSC Hollings Cancer Center and Jane Montealegre, Ph.D., at MD Anderson Cancer Center highlights the untapped potential of federally qualified health centers (FQHCs) to close cervical cancer screening gaps. Published in JAMA Network Open, the research found that if FQHCs met national screening goals, they could reach nearly 2 million additional women—many in rural or low-income areas—and save thousands of lives. Because FQHCs serve patients who often face barriers to care, strengthening screening programs there could be one of the most direct and equitable ways to prevent cervical cancer. As Amboree put it, “We should be investing more, not less, in these community clinics. Cervical cancer could be a disease of the past if we do.”

The Mount Sinai Tisch Cancer Center (TCC) has been named a “Comprehensive Cancer Center” by the National Cancer Institute (NCI), the highest designation awarded to cancer centers in the United States. This recognition places Mount Sinai among the top one percent of cancer centers nationwide and affirms the breadth and depth of its cancer research, clinical excellence, and commitment to health equity. The designation also brings more than $3 million annually to support Mount Sinai’s research and innovation.